Compare · MDLN vs SGHT
MDLN vs SGHT
Side-by-side comparison of Medline Inc. (MDLN) and Sight Sciences Inc. (SGHT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and SGHT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $51.51B, about 86.0x SGHT ($598.6M).
- MDLN has been more active in the news (17 items in the past 4 weeks vs 6 for SGHT).
- MDLN has more recent analyst coverage (25 ratings vs 21 for SGHT).
- Company
- Medline Inc.
- Sight Sciences Inc.
- Price
- -
- -
- Market cap
- $51.51B
- $598.6M
- 1M return
- +10.48%
- -
- 1Y return
- -3.90%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2021
- News (4w)
- 17
- 6
- Recent ratings
- 25
- 21
Sight Sciences Inc.
Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Medline launches right-sized Ranpak packaging solutions in two key distribution centers
- SEC Form EFFECT filed by Medline Inc.
- Medline Inc. announces pricing of secondary offering of Class A common stock
- Chief Legal Officer Liberman Alexander M. was granted 798,680 units of Class B Common Stock, increasing direct ownership by 352% to 1,025,603 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. was granted 520,127 units of Class B Common Stock, increasing direct ownership by 207% to 771,197 units (SEC Form 4)
- Chief Commercial Officer Golwas Douglas P was granted 895,512 units of Class B Common Stock, increasing direct ownership by 164% to 967,560 units (SEC Form 4)
- Chief Executive Officer Boyle James M was granted 2,516,260 units of Class B Common Stock, increasing direct ownership by 7,591% to 1,869,921 units (SEC Form 4)
- Medline Inc. announces launch of secondary offering of Class A common stock
- SEC Form S-1 filed by Medline Inc.
Latest SGHT
- EVP, Operations & R&D Brenton Taylor sold $220,006 worth of shares (20,685 units at $10.64), decreasing direct ownership by 8% to 241,305 units (SEC Form 4)
- Sight Sciences to Present at Two Upcoming Investor Conferences
- Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids
- SEC Form 10-Q filed by Sight Sciences Inc.
- Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance
- Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
- H.C. Wainwright initiated coverage on Sight Sciences with a new price target
- EVP, Operations & R&D Taylor Brenton sold $26,453 worth of shares (2,988 units at $8.85) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Bauerlein Alison sold $223,627 worth of shares (25,260 units at $8.85) as part of a pre-agreed trading plan (SEC Form 4)